<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Medicine and Biomedical Science</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/75C4A53A-2140-4EB0-996B-0C09BA411106"><gtr:id>75C4A53A-2140-4EB0-996B-0C09BA411106</gtr:id><gtr:firstName>Allan</gtr:firstName><gtr:surname>Lawrie</gtr:surname><gtr:orcidId>0000-0003-4192-9505</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800318"><gtr:id>C52C3BBC-556D-4D2E-894F-58DAFEE9D97B</gtr:id><gtr:title>Dissecting the role of Osteoprotegerin and related signalling pathways in the pathogenesis of pulmonary arterial hypertension</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800318</gtr:grantReference><gtr:abstractText>Pulmonary arterial hypertension is a devastating and life threatening condition that often affects the young. The disease is characterised by the loss of blood vessels within the lung. However, the exact mechanisms of the disease process remain unclear. We have evidence from both clinical studies and experiments in the laboratory to suggest that a protein called osteoprotegerin (OPG) is present at abnormally high levels in this condition. I will investigate how OPG and related proteins are controlled and whether the abnormally high level of OPG is actively causing/driving disease or a diagnostic bystander. To do this I will perform studies in animal models of disease and engineer a mouse that over-expresses OPG to test whether these mice develop pulmonary arterial hypertension. In addition I will use new high throughput protein screening techniques to identify the important intermediary molecules with the goal of identifying novel targets for potential new therapies.</gtr:abstractText><gtr:technicalSummary>Pulmonary arterial hypertension (PAH) is a devastating and life threatening condition often affecting young women, limiting their physical capacity, and decreasing life expectancy (median 2.8 years without treatment). Current drug treatments fail to reverse disease, leaving lung transplant as the only curative treatment. Pathologically PAH is characterised by the obliteration of the distal pulmonary arteries. Early endothelial cell (EC) dysfunction and apoptosis, and the subsequent abnormal proliferation and migration of pulmonary artery smooth muscle cells (PA-SMC) are thought to be the major contributing factors but the molecular mechanisms responsible are unknown. I have recently described heightened expression of osteoprotegerin (OPG) in Pulmonary Arterial Hypertension (PAH) patients, and that OPG induces proliferation and migration of pulmonary artery smooth muscle cells in vitro. These data are the first to demonstrate that OPG is increased in PAH and that it regulates PA-SMC proliferation and migration. It is unclear, and I aim to determine whether OPG is causal and/or a potential new biomarker in PAH. To this end, the objectives for this fellowship are to 1) determine the temporal relationship between the pattern of OPG expression and onset/progression of PAH in animal models 2) Determine whether over-expression of OPG expression causes PAH in a transgenic mouse model. 3) Determine whether blocking OPG with a neutralising OPG antibody prevents and/or reverses PAH in animal models, and 4) Identify associated binding partners and signalling processes involved in OPG-induced PA-SMC proliferation and migration. To achieve these objectives I will use a combination of established rodent models for PAH and generate a transgenic mouse that over-expresses OPG in vascular smooth muscle cells. Finally using a systems biology approach, I will identify OPG binding partners and subsequent signalling mechanisms by a combination of Biacore technology, MALDI-TOF mass spectrometry and protein array to determine the key molecules that mediate OPG-induced PA-SMC proliferation and migration. The data generated will provide valuable insights into the role of OPG in that pathogenesis of PAH and potentially identify novel therapeutic targets for the treatment of PAH.</gtr:technicalSummary><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1033771</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine Sheffield</gtr:department><gtr:description>Sheffield Pulmonary Vascular Disease Research Programme</gtr:description><gtr:id>40AA73B0-9197-4B47-99D4-45A96BBA2040</gtr:id><gtr:impact>Manuscripts in press and in preparation. Co-application on current grant applications and the development of a biorepository for patient samples</gtr:impact><gtr:outcomeId>r2TQLo9mrdr-1</gtr:outcomeId><gtr:partnerContribution>Access to patient data and samples for research purposes</gtr:partnerContribution><gtr:piContribution>Intellectual</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mammalian Genetics Unit</gtr:department><gtr:description>MRC Mouse Network - Tissue Remodelling and Fibrosis Research Consortium</gtr:description><gtr:id>A542717B-E152-4456-8A31-F8EA13C1A103</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>ZNxdtKxezuS-1</gtr:outcomeId><gtr:partnerContribution>Contribution of targets for knock-out mice related to fibrosis.</gtr:partnerContribution><gtr:piContribution>Contribution of targets for knock-out mice related to fibrosis.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>86268</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sheffield CV BRU MRes/PhD studentship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4CB22F48-99DE-4D6C-AD81-61C1A1E55766</gtr:id><gtr:outcomeId>13951DE784C0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>205000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Training Fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K002406/1</gtr:fundingRef><gtr:id>CEA2B0DE-642A-4184-B1B4-63E416D20F6A</gtr:id><gtr:outcomeId>XrfjD8pQqPF</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>International Travel Grant</gtr:description><gtr:end>2009-11-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>804CEEA1-B59C-4BE8-949B-E9A45BE59011</gtr:id><gtr:outcomeId>QfnhHRTsjXZ0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cardiovascular Biomedical Research Unit - Sheffield Research Assistant</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>609CE086-A990-4F68-B402-3D69847474A5</gtr:id><gtr:outcomeId>MoLBqwWdULG0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cardiovascular Biomedical Research Unit - Sheffield Post doc</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>687EF30F-B468-4C4C-85C7-C02C34AA9FF4</gtr:id><gtr:outcomeId>SjrZpTYznqB0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>172729</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Clinical Research Training Fellowship</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>972E4D43-EB3C-4984-91DB-71A44FDE33D6</gtr:id><gtr:outcomeId>AA38219A0BC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DTG Studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F6D909B2-7456-4E46-B088-A4D08EA420FE</gtr:id><gtr:outcomeId>R63DcJFnef80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bayer Healthcare Grants 4 Targets</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>Bayer</gtr:fundingOrg><gtr:id>0DD62C91-4516-448B-BA13-E4F1E21611BA</gtr:id><gtr:outcomeId>psvaaNjm4zX0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Biomedical Vacation Scholarship</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>EFD74E30-FE78-4017-B150-306AE173DD0A</gtr:id><gtr:outcomeId>iUgMJPd6xDV0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The disclosure relates to agents that inhibit the activity of osteoprotegerin (OPG) and their use in the treatment of pulmonary hypertension.</gtr:description><gtr:grantRef>G0800318</gtr:grantRef><gtr:id>304EA570-638A-4A35-A685-976C8D780EB8</gtr:id><gtr:impact>Spin-out formed</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>Y9aUgZ9qhZj</gtr:outcomeId><gtr:patentId>WO2013064810</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Targeting OPG in pulmonary hypertension</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The disclosure relates to agents that inhibit the activity of Tumour Necrosis Factor Apoptosis-Inducing Ligand [TRAIL] and their use in the treatment of pulmonary hypertension.</gtr:description><gtr:grantRef>G0800318</gtr:grantRef><gtr:id>B29EF791-DCCE-4FBA-98FD-3550EB9BD170</gtr:id><gtr:impact>Spin-out formed</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>KxNtdXvY1oZ</gtr:outcomeId><gtr:patentId>WO2013061048</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Targeting TRAIL in pulmonary hypetertension</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Through this funding I have established a very thorough cardiac phenotyping program that include analysis of both Right and Left ventricles with conductance pressure volume catheterisation as well as non-invasive techniques using ultrasound and MR imaging</gtr:description><gtr:id>B9D4BCAB-E755-471A-BC68-A5EC0C242B7C</gtr:id><gtr:impact>World class cardiac phenotyping</gtr:impact><gtr:outcomeId>B9DED350046</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Combined Cardiac  haemodynamic phenotyping</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Biorepository comprised of blood samples collected from patients</gtr:description><gtr:id>E08831BE-75CF-4731-83E1-E8A70669B932</gtr:id><gtr:impact>New academic collaborations. Grant submission and papers under review.</gtr:impact><gtr:outcomeId>NoiMTkezxbA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Sheffield Pulmonary Hypertension biorepository</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>VisualSonics ultrasound set up for both mouse and rat echocardiography.</gtr:description><gtr:id>AD020F34-AF26-4F55-8419-6996E6510D7F</gtr:id><gtr:impact>manuscripts</gtr:impact><gtr:outcomeId>N7PM6qPcPQp</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Non-invasive ultrasound imaging of rodents</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4D11F39A-9FA5-420A-B9E2-F01AA788B5AF</gtr:id><gtr:title>From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f32d42dfbc3293568813cb577bace95e"><gtr:id>f32d42dfbc3293568813cb577bace95e</gtr:id><gtr:otherNames>Dawson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>589b5797740269.54753368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A951838-1AF4-4DB5-9AD6-33E548C0760D</gtr:id><gtr:title>Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74ef6c05446c342f04774928d90c91f6"><gtr:id>74ef6c05446c342f04774928d90c91f6</gtr:id><gtr:otherNames>Watson O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>doi_12710_cvr_cvt170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB92526F-C618-4F79-81F2-55533F87635A</gtr:id><gtr:title>miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?</gtr:title><gtr:parentPublicationTitle>Epigenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74fbe7b47b55cb090b67e1778274ea66"><gtr:id>74fbe7b47b55cb090b67e1778274ea66</gtr:id><gtr:otherNames>Rothman AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1750-192X</gtr:issn><gtr:outcomeId>589b57974f05d2.94249429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4443BE5C-3867-4D48-A25F-65B0E34ADEA7</gtr:id><gtr:title>TRAIL Deficient Mice Are Protected from Sugen/Hypoxia Induced Pulmonary Arterial Hypertension</gtr:title><gtr:parentPublicationTitle>Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f32d42dfbc3293568813cb577bace95e"><gtr:id>f32d42dfbc3293568813cb577bace95e</gtr:id><gtr:otherNames>Dawson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>544de83bc51895.65743688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7499CE9F-6337-48A4-94E9-8DCFC16EC3CA</gtr:id><gtr:title>A report on the use of animal models and phenotyping methods in pulmonary hypertension research.</gtr:title><gtr:parentPublicationTitle>Pulmonary circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ed2368592c3b2b34d61256ea9619385"><gtr:id>9ed2368592c3b2b34d61256ea9619385</gtr:id><gtr:otherNames>Lawrie A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-8932</gtr:issn><gtr:outcomeId>544de83b53b609.51381784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DC704A2-FEA0-4400-89C0-A0B797F1DDC7</gtr:id><gtr:title>Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8fb3ab981f9170cc7c6f5a14d8bb1e9"><gtr:id>f8fb3ab981f9170cc7c6f5a14d8bb1e9</gtr:id><gtr:otherNames>Rhodes CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>doi_12710_205_0839OC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6D7259A-F05D-4A3A-99E8-962D271D025D</gtr:id><gtr:title>Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a59e42e9d22616597037c27e2e8b3dbf"><gtr:id>a59e42e9d22616597037c27e2e8b3dbf</gtr:id><gtr:otherNames>Thompson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>589b5796c60986.86514820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90D5A014-46FD-49A3-853B-52108F63C835</gtr:id><gtr:title>The role of the osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ed2368592c3b2b34d61256ea9619385"><gtr:id>9ed2368592c3b2b34d61256ea9619385</gtr:id><gtr:otherNames>Lawrie A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>doi_55f984984a675d4a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75AADE57-A3A2-447C-9834-2B544C828FFD</gtr:id><gtr:title>Heart rate reduction with ivabradine promotes shear stress-dependent anti-inflammatory mechanisms in arteries.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d99fb5bcfb3ed58e1c64bec1b64d384a"><gtr:id>d99fb5bcfb3ed58e1c64bec1b64d384a</gtr:id><gtr:otherNames>Luong L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>589b5797b94a45.90836437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E0A8998-3BA9-43AF-BC42-7E87A8F0FDFB</gtr:id><gtr:title>Pulmonary hypertension in COPD: results from the ASPIRE registry.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59abee5848e8eb42ede19733dd5773b4"><gtr:id>59abee5848e8eb42ede19733dd5773b4</gtr:id><gtr:otherNames>Hurdman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_12710_20_23018917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20CFF9CD-89AF-40DF-817B-2AE015599955</gtr:id><gtr:title>Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8fb3ab981f9170cc7c6f5a14d8bb1e9"><gtr:id>f8fb3ab981f9170cc7c6f5a14d8bb1e9</gtr:id><gtr:otherNames>Rhodes CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>589b57971e8fe0.96676906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AC93002-3FE8-4120-BF2D-292547095E63</gtr:id><gtr:title>Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ed2368592c3b2b34d61256ea9619385"><gtr:id>9ed2368592c3b2b34d61256ea9619385</gtr:id><gtr:otherNames>Lawrie A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>ias4zKYpwmE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>783A0609-CC7D-4705-9EE6-5DB7185D2E24</gtr:id><gtr:title>Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice.</gtr:title><gtr:parentPublicationTitle>Experimental physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20bed27c9b7db9534904f91a3ebfe2b5"><gtr:id>20bed27c9b7db9534904f91a3ebfe2b5</gtr:id><gtr:otherNames>Boehm M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0958-0670</gtr:issn><gtr:outcomeId>58c15c9fc3b550.31710258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF983983-B73F-4B7B-A64C-F63E9B48C4B3</gtr:id><gtr:title>Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline.</gtr:title><gtr:parentPublicationTitle>JACC. Cardiovascular interventions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/240a27c7bd5d10365eaae398f59768ee"><gtr:id>240a27c7bd5d10365eaae398f59768ee</gtr:id><gtr:otherNames>Zhou L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1936-8798</gtr:issn><gtr:outcomeId>56d8b99463d5a7.07390885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D883C7FB-8E05-4A80-8A46-3BFD205F5075</gtr:id><gtr:title>ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59abee5848e8eb42ede19733dd5773b4"><gtr:id>59abee5848e8eb42ede19733dd5773b4</gtr:id><gtr:otherNames>Hurdman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>H3VpWM2DsM6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>214314F7-4926-4B44-975E-2FD678614190</gtr:id><gtr:title>Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b8cfc7ea3a76b19e21343fd04db9125"><gtr:id>8b8cfc7ea3a76b19e21343fd04db9125</gtr:id><gtr:otherNames>McGrath EE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_12710_20_22496351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>980FC336-C70A-4092-8556-AE44AB36300C</gtr:id><gtr:title>Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e5c9d6a4eb987fe54001b6ead326f95"><gtr:id>0e5c9d6a4eb987fe54001b6ead326f95</gtr:id><gtr:otherNames>Hickey PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>589b5796e5a3e4.35102071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A04BFD2-8CA8-44A1-9012-A7EA5E38D791</gtr:id><gtr:title>S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93a6872a1e342f7082c3e084689fb0be"><gtr:id>93a6872a1e342f7082c3e084689fb0be</gtr:id><gtr:otherNames>Spiekerkoetter E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>0083085AB62</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72FBC709-7637-4AC6-A0EF-3197B80ED871</gtr:id><gtr:title>Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93a6872a1e342f7082c3e084689fb0be"><gtr:id>93a6872a1e342f7082c3e084689fb0be</gtr:id><gtr:otherNames>Spiekerkoetter E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>56d8b994a3fd69.60796881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>101A7B6D-08E1-4141-84BB-005AC731D9D7</gtr:id><gtr:title>Elevated plasma CXCL12a is associated with a poorer prognosis in pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a6c8e216647fd0be2c2658db8b4e1d5"><gtr:id>6a6c8e216647fd0be2c2658db8b4e1d5</gtr:id><gtr:otherNames>McCullagh BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55f984984a712958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AE2BDDB-44BF-4FD0-B4E1-7BF82AC9737C</gtr:id><gtr:title>Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ed2368592c3b2b34d61256ea9619385"><gtr:id>9ed2368592c3b2b34d61256ea9619385</gtr:id><gtr:otherNames>Lawrie A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>Hah2wvewrJe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F91D3131-E990-4781-8DA4-9989C3121EB4</gtr:id><gtr:title>Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Pulmonary circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8aeaa46a53b7a6d9ad38fa32c147003"><gtr:id>e8aeaa46a53b7a6d9ad38fa32c147003</gtr:id><gtr:otherNames>Condliffe R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2045-8932</gtr:issn><gtr:outcomeId>pm_12710_20_22558516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>474BBE07-78A7-4AC0-8E07-CA2B493E7683</gtr:id><gtr:title>No evidence for cardiac dysfunction in Kif6 mutant mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88cecb6e7cbb713460745a499b505e58"><gtr:id>88cecb6e7cbb713460745a499b505e58</gtr:id><gtr:otherNames>Hameed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_12710_ne_0054636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6922BE0E-2497-4F99-AA9C-4A831BF3743C</gtr:id><gtr:title>MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74fbe7b47b55cb090b67e1778274ea66"><gtr:id>74fbe7b47b55cb090b67e1778274ea66</gtr:id><gtr:otherNames>Rothman AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>585d67422b9ce2.81050625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FCDB3FC-A20B-46CD-BCCD-8052C4B5D57F</gtr:id><gtr:title>TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b8cfc7ea3a76b19e21343fd04db9125"><gtr:id>8b8cfc7ea3a76b19e21343fd04db9125</gtr:id><gtr:otherNames>McGrath EE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>rEsVZzCohXT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66B30A4A-2A5E-43E6-BD62-1225483A6844</gtr:id><gtr:title>Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64786b8ee6570170299618b14b8bd3ca"><gtr:id>64786b8ee6570170299618b14b8bd3ca</gtr:id><gtr:otherNames>Hameed AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_12710_20_23071256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC29258E-5161-401B-BB01-843410741D7D</gtr:id><gtr:title>Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular interventions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74fbe7b47b55cb090b67e1778274ea66"><gtr:id>74fbe7b47b55cb090b67e1778274ea66</gtr:id><gtr:otherNames>Rothman AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1941-7640</gtr:issn><gtr:outcomeId>56d8b99481e026.39861477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBD9FF3C-29C8-4092-8C5F-E0035D22DD2A</gtr:id><gtr:title>Osteoprotegerin in Cardiometabolic Disorders.</gtr:title><gtr:parentPublicationTitle>International journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a970322fd2c5fbed0006f49e738451d9"><gtr:id>a970322fd2c5fbed0006f49e738451d9</gtr:id><gtr:otherNames>P?rez de Ciriza C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1687-8337</gtr:issn><gtr:outcomeId>56d8b994c587e4.41572557</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800318</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>